This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Drug platforms			
Adeno-associated virus (AAV)-mediated zinc finger nuclease (ZFN) delivery for <i>in vivo</i> gene editing	<i>In vitro</i> and mouse studies suggest AAV-mediated delivery of ZFNs could help treat hemophilia B. Hemophilia B is caused by different Factor IX mutations that decrease its expression, and current gene therapy approaches to increase expression involve <i>ex vivo</i> gene editing. In a mouse model of hemophilia, AAV-mediated delivery of a Factor IX ZFN specifically inserted the wild-type gene at the proper locus and increased Factor IX expression and decreased clot formation time compared with delivery of mock ZFN control. Next steps could include testing the strategy in different models of genetic diseases.	Patent and licensing status unavailable	Li, H. <i>et al. Nature</i> ; published online June 26, 2011; doi:10.1038/nature10177 Contact: Katherine A. High, Howard Hughes Medical Institute and The Children's Hospital of Philadelphia, Philadelphia, Pa. e-mail: high@email.chop.edu
	SciBX 4(27); doi:10.1038/scibx.2011.777 Published online July 14, 2011		